Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis

César Álvarez-González, Ashok Adams, Joela Mathews, Benjamin Turner, Gavin Giovannoni, David Baker, Klaus Schmierer

Annals of Clinical and Translational Neurology · 2017 · 19 citations · 17 references

DOIFull text

Open access

Concepts

Abstract

Abstract Rebound disease following cessation of disease modifying treatment ( DMT ) has been reported in people with both relapsing and progressive multiple sclerosis (pw RMS , pw PMS ) questioning strict separation between these two phenotypes. While licensed DMT is available for pw RMS to counter rebound disease, no such option exists for pw PMS . We report on a pw PMS who developed rebound disease, with 45 Gadolinium‐enhancing lesions on T 1 weighted MRI brain, within 6 months after fingolimod 0.5 mg/day was stopped. Treatment with a short course of subcutaneous cladribine 60 mg led to effective suppression of inflammatory activity and partial recovery with no short‐term safety issues or adverse events.

References

17